The Effect of GLP1 Receptor Aagonist on Cardiovascular Death, Myocardial Infarction or Stroke

A second analysis was made with a meta-analysis of the Harmony Outcomes in Amplitude O. In conclusion and according to the authors, in patients with type 2 diabetes and cardiovascular disease GLP1 receptor agonist reduced cardiovascular events independent of SGLT2 inhibitor use. Dr Benita Arova from the Division of Endocrinology Diabetes and hypertension at the Brigham and Women's Hospital in Boston said: "These findings suggest that the combination of GLP 1 receptor agonist with SGLt2 inhibitors may further reduce cardiovascular risk"